Recombinant Human CD2 His Protein

Name: Recombinant Human CD2 His Protein
Brand: Novus Biologicals
SKU: NBP2-22745
Price: 349 USD
Availability: InStock

Novus Biologicals | Catalog # NBP2-22745

Submit a review

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Source

E. coli

Tag

His

Applications

SDS-PAGE

View all CD2 Proteins and Enzymes »

Product Specifications

Description

A denatured recombinant protein with a N-Terminal His-tag and corresponding to the amino acids 25-209 of Human CD2

Source: E.coli

Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGSMKEITNA LETWGALGQD INLDIPSFQM SDDIDDIKWE KTSDKKKIAQ FRKEKETFKE KDTYKLFKNG TLKIKHLKTD DQDIYKVSIY DTKGKNVLEK IFDLKIQERV SKPKISWTCI NTTLTCEVMN GTDPELNLYQ DGKHLKLSQR VITHKWTTSL SAKFKCTAGN KVSKESSVEP VSCPEKGLD

Purity

>85%, by SDS-PAGE

Predicted Molecular Mass

23.8 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Application Notes

Denatured protein is most likely not the best option for functional studies. It is better suited for Western Blot (WB) or imaging assays.

Protein / Peptide Type

Recombinant Protein

Scientific Data Images for Recombinant Human CD2 His Protein

SDS-PAGE: Recombinant Human CD2 His Protein [NBP2-22745]

SDS-Page: Recombinant Human CD2 Protein [NBP2-22745]

Formulation, Preparation, and Storage

NBP2-22745

Formulation	20 mM Tris-HCl buffer (pH8.0), 10% glycerol, 0.4M UREA
Preservative	No Preservative
Concentration	1 mg/ml
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CD2

CD2, also known as sheep red blood cell receptor (SRBC-R), erythrocyte receptor, LFA-2, and T11, is a type I transmembrane glycoprotein that is expressed on the surface of T cells, natural killer (NK) cells, thymocytes, and dendritic cells (1,2). CD2 is a member of the immunoglobulin (Ig) superfamily and a costimulatory receptor that functions in formation of the immunological synapse and T cell activation and signaling (1). The human CD2 protein is 351 amino acids in length with a theoretical molecular weight of ~40 kDa, but a fully glycosylated protein can weight closer to 50 kDa (1,3). The CD2 protein contains a signal sequence, an extracellular domain (ECD) composed of an Ig-like V-type domain followed by an Ig-like C-type domain, a transmembrane helical domain, and a proline-rich cytoplasmic tail (1,3). CD2 binds with CD58, also called LFA-3, which is a surface glycoprotein expressed by antigen presenting cells (APCs) and other target cells (1,2). While CD58 is the primary ligand for CD2 in humans, it also interacts with CD59 and CD48, albeit with lower affinity (1,2). However, in mice and rats which lack CD58 the main ligand for CD2 is CD48 (4). Research has found that when there is no direct interaction, CD2 co-immunoprecipitates with the T cell receptor (TCR)/CD3 complex (1). CD2 is an adhesion molecule with a variety of functions including actin cytoskeleton rearrangement, immunological synapse formation through T cell-APC binding, thymocyte development and T cell activation, and NK cell activation (1,2). The immunological synapse forms upon T cell-APC engagement and creates a contact zone of supramolecule activation clusters (SMACs) where CD2-CD58 is part of the central SMAC (cSMAC) (2).

The CD2-CD58 interaction has been shown to play a role in anti-tumor immune response, where reduced CD58 signaling is associated with immune escape of tumor cells in various hematological and lymphoid malignancies, but restoration of the signal promotes an anti-tumor response (2,5). Additionally, following cytomegalovirus (CMV) infection, CD2's binding to upregulated CD58 on CMV-infected cells is crucial for the activation and function of adaptive NK cells in the anti-viral response (2). In contrast, in situations where there is an increase in T cell and NK cell activation, like various autoimmune disorders or following organ transplant, costimulatory blockade of CD2-CD58 may be a potential therapeutic treatment approach (1). Mouse and rat xenograft models have shown that blocking the CD2 using anti-CD2 monoclonal antibodies contributes to graft survival and protects against lymphocyte infiltration and inflammatory damage (2).

References

1. Binder C, Cvetkovski F, Sellberg F, et al. CD2 Immunobiology. Front Immunol. 2020;11:1090. https://doi.org/10.3389/fimmu.2020.01090

2. Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a Glance. Front Immunol. 2021;12:705260. https://doi.org/10.3389/fimmu.2021.705260

3. Uniprot (P06729)

4. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. J Exp Med. 1999;190(10):1371-1374. https://doi.org/10.1084/jem.190.10.1371

5. Nishikori M, Kitawaki T, Tashima M, Shimazu Y, Mori M, et al. Diminished CD2 Expression in T cells Permits Tumor Immune Escape. J Clin Cell Immunol. 2016;7:406. https://doi.org/10.4172/2155-9899.1000406

Alternate Names

CD2, LFA-2, T11

Gene Symbol

CD2

Additional CD2 Products

Product Documents for Recombinant Human CD2 His Protein

Download Product Datasheets

Product Specific Notices for Recombinant Human CD2 His Protein

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.